LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.33 3.1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.26

Максимум

1.34

Ключови измерители
By Trading Economics
Приходи	17M -26M
Служители	171
EBITDA	19M -23M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+55.04% upside

Дивиденти
By Dow Jones
Следващи печалби	12.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-24M 78M
Предишно отваряне	-1.77
Предишно затваряне	1.33

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.03.2026 г., 23:01 ч. UTC

Печалби

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

5.03.2026 г., 21:54 ч. UTC

Печалби

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

5.03.2026 г., 21:35 ч. UTC

Значими двигатели на пазара

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

6.03.2026 г., 00:00 ч. UTC

Значими събития в новините

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

5.03.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

5.03.2026 г., 23:33 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Technical Recovery -- Market Talk

5.03.2026 г., 23:27 ч. UTC

Пазарно говорене

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

5.03.2026 г., 22:54 ч. UTC

Пазарно говорене

Печалби

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

5.03.2026 г., 22:50 ч. UTC

Пазарно говорене

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

5.03.2026 г., 22:48 ч. UTC

Печалби

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

5.03.2026 г., 22:46 ч. UTC

Печалби

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

5.03.2026 г., 22:44 ч. UTC

Печалби

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

5.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

5.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

5.03.2026 г., 21:35 ч. UTC

Печалби

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5.03.2026 г., 21:32 ч. UTC

Печалби

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5.03.2026 г., 21:26 ч. UTC

Печалби

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

5.03.2026 г., 21:24 ч. UTC

Печалби

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

5.03.2026 г., 21:23 ч. UTC

Печалби

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

5.03.2026 г., 21:22 ч. UTC

Печалби

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5.03.2026 г., 21:21 ч. UTC

Печалби

Costco February Digitally-Enabled Sales Rose 21.8% >COST

5.03.2026 г., 21:21 ч. UTC

Печалби

Costco Total Co Comparable Sales for February Rose 7.9% >COST

5.03.2026 г., 21:20 ч. UTC

Печалби

Costco February Net Sales Were $21.69 B >COST

5.03.2026 г., 21:20 ч. UTC

Печалби

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5.03.2026 г., 21:20 ч. UTC

Печалби

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5.03.2026 г., 21:19 ч. UTC

Печалби

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

5.03.2026 г., 21:18 ч. UTC

Печалби

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

5.03.2026 г., 21:18 ч. UTC

Печалби

Costco 2Q Same-Store Sales Up 7.4% >COST

5.03.2026 г., 21:15 ч. UTC

Печалби

Costco 2Q EPS $4.58 >COST

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

55.04% нагоре

12-месечна прогноза

Среден 2 USD 55.04%

Висок 2 USD

Нисък 2 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.